<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36052">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637232</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.104160</org_study_id>
    <nct_id>NCT02637232</nct_id>
  </id_info>
  <brief_title>Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)</brief_title>
  <acronym>MUSE</acronym>
  <official_title>Mirvaso® Utilisation and Patient Satisfaction Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the level of satisfaction among patients to whom
      Mirvaso® / Onreltea TM (trade mark) is prescribed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction among patients to whom Mirvaso®/OnrelteaTM is prescribed (% of subjects across score per question).</measure>
    <time_frame>Week 4</time_frame>
    <description>% of subjects across score per question.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">302</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Mirvaso® / Onreltea TM</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mirvaso® / Onreltea TM</intervention_name>
    <arm_group_label>Mirvaso® / Onreltea TM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with persistent facial erythema of rosacea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients to whom the physician has already decided to prescribe Mirvaso® /OnrelteaTM
             according to package insert
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 17, 2016</lastchanged_date>
  <firstreceived_date>December 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
